Tumor and Normal-Tissue Distribution of Radioactivity in Athymic Mice Implanted Subcutaneously with MDA-MB-361 Human Breast Cancer Xenografts at 72 h After Injection of 111In-DTPA-Pertuzumab
| Not blocked | Blocked | |||
|---|---|---|---|---|
| Site | %ID/g | T/NT | %ID/g | T/NT |
| Blood | 5.9 ± 0.4 | 5.9 ± 1.4 | 5.6 ± 0.7 | 1.4 ± 0.3 |
| Heart | 1.7 ± 0.2 | 20.7 ± 6.4 | 1.8 ± 0.2 | 4.5 ± 0.8 |
| Lungs | 3.5 ± 0.4 | 9.5 ± 2.4 | 3.1 ± 0.6 | 2.6 ± 0.6 |
| Liver | 8.5 ± 1.2 | 4.1 ± 1.6 | 8.4 ± 1.1 | 0.9 ± 0.2 |
| Spleen | 7.8 ± 2.0 | 4.4 ± 1.3 | 5.2 ± 0.6 | 1.5 ± 0.3 |
| Kidneys | 15.3 ± 0.4 | 2.3 ± 0.6 | 12.8 ± 1.9 | 0.6 ± 0.0 |
| Small intestine | 2.0 ± 0.3 | 18.1 ± 6.4 | 2.0 ± 0.1 | 3.9 ± 0.5 |
| Large intestine | 1.5 ± 0.1 | 22.8 ± 7.5 | 1.1 ± 0.0 | 6.8 ± 0.5 |
| Muscle | 0.9 ± 0.1 | 37.9 ± 9.5 | 0.9 ± 0.1 | 8.8 ± 0.1 |
| Tumor | 34.6 ± 9.9* | 1.0 ± 0.0 | 7.8 ± 0.5 | 1.0 ± 0.0 |
↵* Statistically significant difference (P < 0.01), compared with blocked group.
Groups of 3–4 tumor-bearing athymic mice were injected intravenously with 111In-DTPA-pertuzumab (10 μg) without (not blocked) or with (blocked) preinjection of 1 mg of unlabeled pertuzumab.